| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 80, 3191-3195, Copyright © 1995 by Endocrine Society
ARTICLES |
AB Grey, JP Stapleton, MC Evans and IR Reid
Department of Medicine, University of Auckland, New Zealand.
There is growing interest in the use of anti-estrogens as agents of disease prevention. Studies of women with breast cancer suggest that the synthetic anti-estrogen tamoxifen may reduce the incidence of cardiovascular disease, but the effects of this agent on cardiovascular risk factors in healthy women have not been studied. We have performed a two-year, randomized, placebo-controlled trial to assess the effects of tamoxifen 20 mg/day on serum lipids, fibrinogen, and body composition in 57 normal postmenopausal women. Tamoxifen treatment lowered levels of serum cholesterol by (mean +/- SE) 12 +/- 2%, low density lipoprotein cholesterol by 19 +/- 3%, and fibrinogen by 18 +/- 4% (P < 0.0001 vs. placebo for each). Levels of high density lipoprotein cholesterol were not altered by tamoxifen, but the ratio of total cholesterol to HDL-cholesterol decreased by 11 +/- 4% (P < 0.001 vs. placebo). Tamoxifen did not affect levels of triglycerides, high density lipoprotein cholesterol subfractions, apolipoprotein A1, or glucose, and did not change body weight, body mass index, or body fat distribution. We conclude that tamoxifen significantly reduces the levels of atherogenic lipids and fibrinogen in normal postmenopausal women. The results suggest that the anti-estrogens may substantially reduce the risk of cardiovascular disease, which remains the most common cause of death among postmenopausal women.
This article has been cited by other articles:
 |
|
 |
|
  D. J. Lenihan and F. J. Esteva Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer Oncologist, December 1, 2008; 13(12): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Johansson, S. Gandini, A. Guerrieri-Gonzaga, S. Iodice, M. Ruscica, B. Bonanni, M. Gulisano, P. Magni, F. Formelli, and A. Decensi Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer Cancer Res., November 15, 2008; 68(22): 9512 - 9518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Perez Appraising Adjuvant Aromatase Inhibitor Therapy Oncologist, November 1, 2006; 11(10): 1058 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Ryan and P. E. Goss Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer Oncologist, July 1, 2006; 11(7): 718 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Fountaine, Y. Nishizawa, G. Wei, L. Dogolo, A. Calcagni, and M. J. Gardner Clinical pharmacology of lasofoxifene in Japanese and white postmenopausal women. J. Clin. Pharmacol., June 1, 2006; 46(6): 693 - 699. [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Bushnell and L. B. Goldstein Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis Neurology, October 12, 2004; 63(7): 1230 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid, R. Eastell, I. Fogelman, J. D. Adachi, A. Rosen, C. Netelenbos, N. B. Watts, E. Seeman, A. V. Ciaccia, and M. W. Draper A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women Arch Intern Med, April 26, 2004; 164(8): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Simon, P. Boutouyrie, J.M. Simon, B. Laloux, C. Tournigand, A.I. Tropeano, S. Laurent, and P. Jaillon Influence of Tamoxifen on Carotid Intima-Media Thickness in Postmenopausal Women Circulation, December 3, 2002; 106(23): 2925 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cucinelli, L. Soranna, D. Romualdi, G. Muzj, S. Mancuso, and A. Lanzone The Effect of Raloxifene on Glyco-Insulinemic Homeostasis in Healthy Postmenopausal Women: A Randomized Placebo-Controlled Study J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4186 - 4192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Lawrence, P. C. Adamson, R. Caruso, C. Chow, D. Kleiner, R. F. Murphy, D. J. Venzon, M. Shovlin, M. Noone, M. Merino, et al. Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations J. Clin. Oncol., May 15, 2001; 19(10): 2754 - 2763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cushman, J. P. Costantino, R. P. Tracy, K. Song, L. Buckley, J. D. Roberts, and D. N. Krag Tamoxifen and Cardiac Risk Factors in Healthy Women : Suggestion of an Anti-inflammatory Effect Arterioscler. Thromb. Vasc. Biol., February 1, 2001; 21(2): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Harnish, M. S. Scicchitano, S. J. Adelman, C. R. Lyttle, and S. K. Karathanasis The Role of CBP in Estrogen Receptor Cross-Talk with Nuclear Factor-{kappa}B in HepG2 Cells Endocrinology, September 1, 2000; 141(9): 3403 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Herrington, B. E. Pusser, W. A. Riley, T. Y. Thuren, K. B. Brosnihan, E. A. Brinton, and D. B. MacLean Cardiovascular Effects of Droloxifene, a New Selective Estrogen Receptor Modulator, in Healthy Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1606 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. louffe Jr. Selective Estrogen Receptor Modulators (SERMs) in Clinical Practice Reproductive Sciences, January 1, 2000; 7(1_suppl): S38 - S46. [Abstract] [PDF]
|
|
|
|
|
|
G. W. de Valk-de Roo, C. D.A. Stehouwer, P. Meijer, V. Mijatovic, C. Kluft, P. Kenemans, F. Cohen, S. Watts, and C. Netelenbos Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women : A 2-Year, Placebo-Controlled Study Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2993 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Pinkerton and R. Santen Alternatives to the Use of Estrogen in Postmenopausal Women Endocr. Rev., June 1, 1999; 20(3): 308 - 320. [Abstract] [Full Text]
|
|
|
|
|
|
F. Cosman and R. Lindsay Selective Estrogen Receptor Modulators: Clinical Spectrum Endocr. Rev., June 1, 1999; 20(3): 418 - 434. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1993 - 2000. [Full Text]
|
|
|
|
 |
|
 B. W. Walsh, L. H. Kuller, R. A. Wild, S. Paul, M. Farmer, J. B. Lawrence, A. S. Shah, and P. W. Anderson Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women JAMA, May 13, 1998; 279(18): 1445 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R. Reid, D. J. Wattie, M. C. Evans, and J. P. Stapleton Testosterone Therapy in Glucocorticoid-Treated Men Arch Intern Med, June 10, 1996; 156(11): 1173 - 1177. [Abstract] [PDF]
|
|
|
|
 |
|
 Tamoxifen and Cardiovascular Morbidity Journal Watch Cardiology, January 1, 1996; 1996(101): 14 - 14. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
